Can Amgen Balance Efficacy, Safety With KRAS/PD-1 Combination?
Data presented during the weekend at WCLC for Lumakras with Keytruda or Tecentriq raised questions about elevated liver toxicity and a lackluster response rate.
You may also be interested in...
Expectations Of Lumakras ESMO Late-Breaker Build As Roche Plays KRAS Catch-Up
Amgen secured a last-minute slot as a late-breaker study with Lumakras, appearing to give it the upper hand on rival Mirati once again.
Amgen’s Lumakras Succeeds In Confirmatory Lung Cancer Trial
Amgen said its KRAS G12C inhibitor Lumakras (sotorasib) bested docetaxel in a Phase III clinical trial on the primary endpoint of progression-free survival in second-line-plus non-small cell lung cancer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: what Amgen’s $3.7bn ChemoCentryx buy means; Lilly’s CEO on US drug pricing legislation; Pfizer’s GBT acquisition; new data for Amgen’s KRAS inhibitor combo; and a major China ADC alliance for Sanofi.